Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens
Study Details
Study Description
Brief Summary
This clinical study is to provide clinical performance data comparing the test lens (Deseyne [vifilcon C] daily disposable soft contact lens) to a control lens (1-Day Acuvue Moist [etafilcon A] daily disposable soft contact lens) in the same indication for use (single use prior to removal followed by a fresh lens upon the next lens wear exposure). The study is designed to test the hypothesis that the test lens is substantially equivalent to the control lens in like indications for use.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
A multicenter, randomized, active-controlled, open-label study design will be used to compare the clinical performance of the Deseyne (vifilcon C) test soft contact lens to the similarly indicated 1-Day Acuvue® Moist® (etafilcon A) control soft contact lens.
Study participation is approximately 90 days in duration and will consist of approximately 80 subjects assigned in a 2:1 ratio to test or control lens bilaterally, respectively. Subjects must be otherwise healthy, with myopia between -1.00 D and -6.00 D and astigmatism no greater than 1.00 D that does not interfere with VA.
At the Screening Visit, approximately two-thirds of the eligible subjects will be randomized to receive the test lens (Deseyne [vifilcon C] lenses) and the other one-third eligible subjects will be randomized to receive the control lens (1-Day Acuvue Moist [etafilcon A] lenses). At the Dispensing Visit (Visit 2), subjects will be provided with test or control lenses as part of the dispensing package, along with instructions for the use and care of the lenses. They will be recommended unpreserved lubricating/rewetting solution for use as needed during the study.
Subjects will wear their assigned lenses bilaterally on a daily wear basis, for a minimum of 6 hours/day throughout the study (no maximum time is mandated, as long as subjects do not sleep in their lenses), with additional visits planned for 1 Week (Visit 3), 1 Month (Visit 4), 2 Months (Visit 5), and 3 Months/Exit Visit (Visit 6).
This study follows United States Food and Drug Administration (FDA) Premarket Notification 510(k) Guidance for Daily Wear Contact Lenses adopted in May 1994, and any unpublished subsequent policy declarations.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Test lens. Deseyne Daily Disposable Contact Lens Test contact lens to be worn as a daily disposable soft (hydrophilic) contact lens, to be discarded daily. Individual new lens placed daily for a period of 90 consecutive days, bilaterally. Follow-up visits are 1 week, 1 month, 2 months, and 3 months after dispensing. |
Device: Deseyne Daily Disposable Contact Lens (Test Device)
Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
|
| Active Comparator: Control lens. 1-Day Acuvue Moist Daily Disposable Contact Lens Control lens to be worn as a daily disposable soft (hydrophilic) contact lens, to be discarded daily, Individual new lens placed daily for a period of 90 consecutive days, bilaterally. Follow-up visits are 1 week, 1 month, 2 months, and 3 months after dispensing. |
Device: Deseyne Daily Disposable Contact Lens (Test Device)
Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
|
Outcome Measures
Primary Outcome Measures
- Primary Effectiveness Outcome Measure [Baseline, 1 mo., 2 mo., 3 mo.]
logMAR Visual Acuity, Each eye, change from baseline at each follow up visit
Secondary Outcome Measures
- Secondary Effectiveness Outcome [Follow up visits 1 mo., 2 mo., 3 mo.]
Lens deposits [Type, percent, corneal location, degree.] Change from baseline at each follow up visit.
- Wettability [Initial and each follow up visit 1 mo, 2 mo, 3 mo.]
Analog Scale 0-4 (0=100% wettable, 4=more than one dry spot greater than 0.5mm
- Lens Movement [Initial and each follow up visit 1 mo., 2 mo., 3 mo.]
Analog scale 0-4 (0= adequate, 4= adherence to cornea)
- Lens Centration [Initial and each follow up visit 1 mo, 2 mo, 3mo.]
Analog scale 0-4 (0=superior cornea, 4= inferior cornea)
Other Outcome Measures
- Primary Safety Outcome Measure [At any time during the study and up to final visit at 3 months (90 days.)]
Quantative and qualitative slit lamp findings including corneal edema [epithelial, stromal], corneal infiltrates, corneal vascularization, corneal staining, palpebral conjunctival injection, conjunctival hyperemia, and limbal injection. Standardized Analog scale 0-4 with 0=no finding, and 4 being Severe finding.
- Secondary Safety Outcome Measures [At any time during the study and up to final visit at 3 mo (90 days.)]
Adverse reactions (serious and incidental), adverse device effects, pinhole VA [for eyes with a 2-line decrease in BCVA logMAR or worse from baseline]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 to 40 years of age on the date the informed consent form (ICF) is signed
-
Presence of clear central corneas and absence of any anterior segment disorders in each eye
-
Presence of myopia and requirement for lens correction from -1.00 D to -6.00 D in each eye
-
Best-corrected distance visual acuity (BCDVA) of 50 ETDRS letters (0.1 logMAR) or better in each eye
-
Be an adapted soft contact lens wearer in each eye and agree to wear study lenses in each eye on a daily wear basis and not wear a non-study lens for approximately 3 months
-
Able and willing to comply with all treatment and follow-up/study procedures
-
Able to read, understand, and provide written informed consent on the IRB-approved ICF and provide authorization as appropriate for local privacy regulations
Exclusion Criteria:
-
Participation in any drug or device clinical investigation within 2 weeks prior to Screening and/or during the period of study participation
-
Women of childbearing potential (those who are not surgically sterilized or postmenopausal) who meet any of the following conditions:
-
Currently pregnant
-
Plans to become pregnant during the study
-
Currently breastfeeding
-
History of gas permeable lens wear in either eye within 30 days prior to Screening or history of polymethylmethacrylate lens wear in either eye within 3 months prior to Screening
-
Current monovision, multifocal, or toric contact lens wear in either eye
-
In either eye, current nonabsorbable punctal plug or implantation of absorbable punctal plug within 2 to 6 months (depending on type of absorbable plug) prior to Screening, or punctal plug removal within 2 months prior to Screening. Permanent punctal occlusion in 1 or more puncta or nasolacrimal duct obstruction in either eye is excluded
-
Use of any prescription ocular medication throughout the duration of the study. Prescription eyedrops for dry eye disease (eg, Restasis, Xiidra, Cequa, Eysuvis), as well as nasally administered Tyrvaya, must be discontinued 2 weeks prior to Screening and are prohibited throughout the duration of the study Clinical Study Protocol Version 3.0, 26 April 2023 Page 17 of 66 Bruno Vision Care Protocol 22001
-
Use of over-the-counter eyedrops (eg, oxymetazoline, naphazoline, ketotifen, etc.), except for unpreserved lubricant eyedrops or artificial tears (eg, Systane, Refresh), within 1 week prior to Screening and throughout the duration of the study
-
Use of any systemic or topical medications that may, in the Investigator's opinion, affect ocular physiology or lens performance
-
Anisometropia (spherical equivalent) >2.00 D
-
Ocular astigmatism >1.00 D in either eye
-
Amblyopia in either eye
-
Aphakia in either eye
-
Active ocular disease (eg, dry eye disease, blepharitis, conjunctivitis, keratitis, etc.) in either eye. Subjects must be symptom free for at least 7 days
-
History or evidence of ocular infection within 30 days prior to Screening
-
History or evidence of ocular herpes simplex or ocular herpes zoster
-
Any grade corneal infiltrates in either eye
-
Grade ≥2 finding in either eye during slit lamp examination
-
Any "Present" finding in either eye during slit lamp examination that, in the Investigator's opinion, may interfere with contact lens wear
-
Any scar or neovascularization within the central 4 mm of the cornea in either eye. Subjects with minor peripheral corneal scarring (not extending into the central area) that, in the Investigator's opinion, does not interfere with contact lens wear are eligible to participate in this study
-
History of any corneal surgery (eg, refractive surgery or therapeutic) in either eye
-
Any systemic disease currently affecting ocular health or which, in the Investigator's opinion, may have an effect on ocular health in either eye during the course of the study
-
Allergy to any component in the study care products
-
Meet any of the following criteria:
-
Subject is an employee of the investigative site
-
Subject or a member of the subject's household is an ophthalmologist, an optometrist, an optician, or an ophthalmic assistant/technician
-
Subject or a member of the subject's household is an employee of a manufacturer of contact lenses or contact lens care products
-
Subject or a member of the subject's household is an employee of a market research firm -
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Christopher Pearson, O.D. | Longwood | Florida | United States | 32779 |
| 2 | Shane R Kannarr, OD | Pittsburg | Kansas | United States | 66762 |
| 3 | Athens Eye Care | Athens | Ohio | United States | 45701 |
| 4 | Stephen Montaquila, O.D. | Warwick | Rhode Island | United States | 02888 |
| 5 | David G Evans, OD | Memphis | Tennessee | United States | 38119 |
Sponsors and Collaborators
- Bruno Vision Care
Investigators
- Study Director: Charles Slonim, MD, iuvobioscience
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BrunoVisionCare22001